Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife App from Ypsomed.
The partnership between Ypsomed and Dexcom means the full integration of glucose values from Dexcom's G6 sensors into Ypsomed's therapy management solution. As a result, users of Dexcom CGM and the mylife YpsoPump insulin pump will have all therapy-relevant data in the mylife App on their smartphone. Every five minutes, the CGM sensor will send the current glucose values to the mylife App, where the current glucose reading and trend graph will be displayed. In addition, the mylife App will alert its users when glucose values are too high or too low. Configuration and sensor settings will be available directly in the mylife App. Users will be able to send their CGM and insulin pump data wirelessly from the mylife App to the mylife Cloud and share it with their physician or caregivers. The product integration is expected to be available in late 2020 / early 2021 in Europe by a convenient and free update of the mylife App without the need to replace the current insulin pump.
"This partnership is an important milestone in the improvement of diabetes therapy and further strengthens our product proposition. We are impressed by the quality and dedication of Dexcom and are pleased to collaborate with the market leader in CGM to enable a better outcome for people with diabetes",
comments Simon Michel, CEO Ypsomed, on the partnership.
"We are excited about this partnership with Ypsomed due to their robust presence in Europe, significant experience in the industry and competitively priced pump that delivers outstanding features and functionality,"
said Rick Doubleday, EVP and chief commercial officer at Dexcom.
"We look forward to Ypsomed working with both our current G6 system and TypeZero algorithm, as well as eventually our next generation Dexcom G7 CGM."
The integration of Dexcom CGM data is significant step forward in Ypsomed's mylife Loop program. The goal of the program is a modular and therefore customizable diabetes therapy system with an insulin pump completely controllable via the smartphone, and the future option of adding a hybrid closed loop feature powered by the Dexcom TypeZero algorithm.
Media Contact Europe:
Stephanie Libous | Stephanie.Libous@allisonpr.com
Jim Selman | Jim.Selman@allisonpr.com
Media Contact US:
About Ypsomed Holding AG
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees. Additional information is available under www.ypsomed.com.
About DexCom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.